Brief: aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT Study in Pulmonary Sarcoidosis
14/05/2024 13:43
May 14 (Reuters) - aTyr Pharma Inc LIFE.O :
* ATYR PHARMA ANNOUNCES SECOND POSITIVE DSMB REVIEW FOR
EFZOFITIMOD IN PHASE 3 EFZO-FIT™ STUDY IN PULMONARY SARCOIDOSIS
* ATYR PHARMA INC - FINDINGS FURTHER SUPPORT FAVORABLE
SAFETY
PROFILE OF EFZOFITIMOD
* ATYR PHARMA INC - INDEPENDENT DATA AND SAFETY MONITORING
BOARD
(DSMB) RECOMMENDS CONTINUATION OF STUDY WITHOUT ANY
MODIFICATIONS
Source text for Eikon: ID:nGNX8zJ9Z8
Further company coverage: LIFE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on aTyr Pharma
See all newsBrief: Atyr Pharma Announces Research Collaboration With Montefiore Einstein
U.S. STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
US STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
U.S. STOCKS ON THE MOVE-CoreWeave, Versant Media, BlackBerry
aTyr rises as FDA aligns on late-stage lung disease study plan